First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients

The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).

NCT Number	NCT07708116
Lead Sponsor	Centauri Therapeutics Limited
Conditions	Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization, Bacterial Infections
Enrollment	104 participants
Start Date	2026-06-16
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-16